Sirolimus is associated with longer relapse-free survival than cyclosporine in autoimmune hemolytic anemia and evans syndrome: a retrospective cohort study

This single-center retrospective cohort study compared sirolimus plus glucocorticoids with cyclosporine plus glucocorticoids in 37 and 35 patients with autoimmune hemolytic anemia/Evans syndrome, evaluating treatment response, long-term relapse, and exploratory patient-reported outcomes (PROs). Response and relapse were assessed longitudinally, and relapse-free survival was analyzed using time-to-event methods. PRO data (SF-36/HADS/FACIT) were available only for subsets of the sirolimus cohort and were not collected in the cyclosporine group. No statistically significant differences in overall or complete response rates were detected between the sirolimus (78.4% and 47.3%) and cyclosporine (80.0% and 52.8%) groups (P > 0.05). Median relapse-free survival was not reached in the sirolimus group versus 1455 days in the cyclosporine group (P < 0.05), and the overall relapse rate was lower (16.2% vs. 35.0%; P < 0.05). These findings are hypothesis-generating given the nonrandomized design, small heterogeneous cohort, baseline imbalances, and incomplete drug-level monitoring, and require confirmation in prospective studies.

Authors

Institutions

Publication Details

Journal
Autoimmunity
Published
2026-11-16
DOI
https://doi.org/10.1080/08916934.2026.2760607
Primary Topic
Blood groups and transfusion
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sirolimus is associated with longer relapse-free survival than cyclosporine in autoimmune hemolytic anemia and evans syndrome: a retrospective cohort study

Limin Xing, Huaquan Wang, Rong Fu, Guanyu Luo et al.
Autoimmunity
Blood groups and transfusion
article

Sirolimus is associated with longer relapse-free survival than cyclosporine in autoimmune hemolytic anemia and evans syndrome: a retrospective cohort study

Limin Xing, Huaquan Wang, Rong Fu, Guanyu Luo, Ziying Zhang, Zonghong Shao, Wen Qü, Lijuan Li, Zhang Yang, Yuhong Wu, Hong Liu, Jia Song, Jiajun Wan
article en

Abstract

This single-center retrospective cohort study compared sirolimus plus glucocorticoids with cyclosporine plus glucocorticoids in 37 and 35 patients with autoimmune hemolytic anemia/Evans syndrome, evaluating treatment response, long-term relapse, and exploratory patient-reported outcomes (PROs). Response and relapse were assessed longitudinally, and relapse-free survival was analyzed using time-to-event methods. PRO data (SF-36/HADS/FACIT) were available only for subsets of the sirolimus cohort and were not collected in the cyclosporine group. No statistically significant differences in overall or complete response rates were detected between the sirolimus (78.4% and 47.3%) and cyclosporine (80.0% and 52.8%) groups (P > 0.05). Median relapse-free survival was not reached in the sirolimus group versus 1455 days in the cyclosporine group (P < 0.05), and the overall relapse rate was lower (16.2% vs. 35.0%; P < 0.05). These findings are hypothesis-generating given the nonrandomized design, small heterogeneous cohort, baseline imbalances, and incomplete drug-level monitoring, and require confirmation in prospective studies.

AutoimmunityVol. 59(1)
Tianjin Medical University General Hospital (CN), Baoding People's Hospital (CN)
Blood groups and transfusion
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon